The DDAH1 (dimethylarginine dimethylaminohydrolase 1) antibody is a research tool designed to detect and study the DDAH1 protein, a key enzyme in the regulation of nitric oxide (NO) synthesis. DDAH1 catalyzes the hydrolysis of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), thereby modulating NO production. As NO is critical for vascular homeostasis, immune response, and neural signaling, DDAH1 plays a pivotal role in cardiovascular health, endothelial function, and inflammatory processes.
Dysregulation of DDAH1 has been implicated in pathologies such as hypertension, atherosclerosis, diabetes-related complications, and chronic kidney disease. The antibody enables researchers to investigate DDAH1 expression levels, localization, and interactions in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence.
Studies using DDAH1 antibodies have contributed to understanding its tissue-specific roles, post-translational modifications, and responses to oxidative stress or therapeutic interventions. Commercial DDAH1 antibodies are typically validated for specificity and sensitivity, though cross-reactivity with DDAH2 (a related isoform) should be ruled out in experimental setups. Its application advances research into NO-mediated pathways and potential therapeutic targets for vascular and metabolic disorders.